TNGX

Tango Therapeutics' stock price has been significantly impacted by several events in the past six months. The stock jumped 36.3% following the announcement of plans to initiate a pivotal Phase 2 trial for vopimetostat monotherapy in second-line MTAP-deleted pancreatic cancer during 2026, supported by positive Phase 1/2 clinical data. Other contributing factors included a clinical collaboration with Erasca, strong growth in collaboration revenue, and presentations at major healthcare conferences. Analyst firms have also shown strong support, with several increasing their price targets for TNGX shares. The stock has seen a remarkable 1,965% return over the past year. On April 15, 2026, the President of R&D, Crystal Adam, exercised stock options and subsequently sold shares.